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CASE REPORT
Skin rash associated with intravitreal 
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Purpose: The purpose of this observational case report is to describe a case of skin rash after 
intravitreal use of bevacizumab.
Methods: A 50-year-old man with choroidal neovascularization in the right eye due 
to age-related macular degeneration was treated with three intravitreal injections of 
bevacizumab.
Results: Twelve days after the ﬁ  rst injection, the patient developed a maculopapular rash on 
his forehead and on both temporal regions around his eyes. The rash disappeared eight days 
after treatment with topical corticosteroids. A skin rash with the same distribution reappeared 
14 days after the second and 10 days after the third injection. Similarly, it disappeared ﬁ  ve and 
seven days after the use of the same treatment. The follow-up period was 15 months after the 
third injection. During the follow-up period the rash did not reappear.
Conclusion: This case report may initiate further investigation of similar cases to support 
this observation, as there are a lack of reports of skin rash after intravitreal administration of 
bevacizumab.
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Case report
Bevacizumab is a recombinant humanized antibody that binds to all isoforms of 
vascular endothelial growth factor (VEGF). It is designed for intravenous use in 
the treatment of metastatic colorectal cancer,1 but it is also offered as an off-label 
intravitreal application for retinal disorders, such as exudative age-related macular 
degeneration (ARMD).2 We report the development of a skin rash in a patient with 
macular choroidal neovascularization (CNV) due to ARMD, who was treated with 
repeated intravitreal injections of bevacizumab.
A 50-year-old man presented to us with decrease of vision in the right eye (RE) 
for the last two months. Fundus examination, ﬂ  uorescein angiography (FA) and opti-
cal coherence tomography (OCT) revealed a parafoveal minimally classic CNV with 
exudative lesions in the right eye due to ARMD. Visual acuity (VA) was 3/10 RE 
(−0.5 −2.25 145°) and 10/10 left eye (LE) (−1.0 −1.5 35°). A treatment with repeated 
intravitreal injections of bevacizumab was decided and the patient signed an informed 
consent form for the acceptance of this treatment.
All the intravitreal injections were carried out in the operation theatre. Topical 
proparacaine hydrochloride 0.5% was applied to the ocular surface followed by prepa-
ration with 5% povidone iodine. A cotton-tipped applicator soaked in proparacaine 
hydrochloride was then applied to the injection site 4 mm posterior to the limbus. 
The intravitreal dose of bevacizumab (Avastin) was 1.25 mg/0.05 ml. Bevacizumab 
was placed in a 0.5 ml syringe with an integrated 31-gauge needle and 0.2 ml was Clinical Ophthalmology 2009:3 130
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injected into the vitreous. Indirect ophthalmoscopy was 
used to conﬁ  rm uneventful intravitreal placement of the 
suspension.
Twelve days after the first intravitreal injection of 
bevacizumab (1.25 mg), a maculopapular rash appeared on 
the forehead (Figure 1), as well as on both temporal regions 
around the eyes (Figure 2), while he didn’t have this speciﬁ  c 
rash elsewhere on the body. The rash disappeared seven days 
later after treatment with topical corticosteroids (ointment 
betamethazone valerate 0.1% three times a day on the area 
of skin rash). A skin rash with the same distribution was 
reappeared 14 and 10 days after the second and the third 
intravitreal injection of bevacizumab, which also disappeared 
seven and 10 days after the intravitreal injection.
After the third injection, the VA of the RE improved to 
8/10 and the exudative lesions disappeared. The patient was 
followed-up without any treatment until 15 months after the 
third injection. The VA remains stable without recurrence 
of the exudative lesions. In addition, the skin rash did not 
reappear during the whole follow-up period.
The most common side effects associated with the 
intravenous use of bevacizumab are hemorrhage, arterial 
thromboembolism, gastrointestinal perforation, and 
hypertension.3 Gotlib and colleagues4 described a rash 
similar to our patient’s after intravenous use of bevacizumab 
for the treatment of colon cancer. Other dermatologic side 
effects which have been described after the systemic use of 
bevacizumab include exfoliative dermatitis5 and unspeciﬁ  ed 
rash.6 The intravitreal administration of bevacizumab may be 
followed by side effects including inﬂ  ammation or uveitis, 
endophthalmitis, lens injury, cataract progression, subretinal 
hemorrhage, retinal detachment, blood pressure elevation and 
retinal pigment epithelium tears.7
We believe that the development of our patient’s rash 
was linked to the intravitreal injection of bevacizumab, as 
it always appeared with the same distribution after every 
of the three repeated intravitreal injections. All three times, 
the skin rash appeared 10–14 days after the injection and 
disappeared 7–10 days later after the use of treatment with 
topical corticosteroids. Further, the skin rash did not reappear 
Figure 1 The maculopapular rash on the patient’s forehead.Clinical Ophthalmology 2009:3 131
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when the intravitreal injections were interrupted for a period 
of 15 months after the third injection.
We believe that this rash was not a local reaction to the 
topically administered antibiotics or the betadine, as it was 
developed not only around the treated eye but also around 
the other eye.
To our knowledge, this is the ﬁ  rst report of development 
of a skin rash after intravitreal injection of bevacizumab. 
Skin rashes have not yet been reported with ranibizumab, the 
antibody fragment of bevacizumab, which has been approved 
for the treatment of ARMD. We have also not documented 
any case of skin rash after intravitreal administration of 
ranibizumab.
A possible explanation for the development of this 
adverse event is the functional similarity of VEGF with the 
epidermal growth factor receptor (EGFR). Skin rashes are a 
typical side effect of EGFR antagonists, such as the antibody 
cetuximab.8 They usually develop two weeks after the intra-
venous administration of the drug and affect the face, trunk, 
and extremities. Furthermore, the blockage of VEGF by other 
drugs such as BAY 43-9006 results to the development of 
skin rashes along with its other side effects.9
In conclusion, a possible rare side effect that may occur 
after an intravitreal injection of bevacizumab is the devel-
opment of a skin rash. This case report may initiate further 
investigation of similar cases to support this observation, 
as there are a lack of reports of skin rash after intravitreal 
administration of bevacizumab.
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Figure 2 The maculopapular rash on the patient’s temporal regions around his eyes: right (A) and left (B).